Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer
NCT ID: NCT05493683
Last Updated: 2022-10-21
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE2
Total Enrollment
29 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-08-01
Study Completion Date
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Among patients with colonrectal cancer, 5% were HER-2 positive, but the immunohistochemical results were mostly HER-2 2 +, which did not meet the indications of HER-2 targeting drugs. Disitamab Vedotin , which was listed in China last year, achieved similar results in HER-2 2+ and 3+, according to a clinical trial for breast cancer, suggesting that patients with colonrectal cancer may benefit from it. Tislelizumab is a PD-1 monoclonal antibody, which has been approved for a variety of tumors. It was reported that anti-HER-2 treatment can improve the tumor immune microenvironment and improve the efficacy of immunotherapy. At the same time, our previous studies showed that anti-PD-1 combined with Disitamab Vedotin can significantly inhibit the growth of colon tumor in mice. Therefore, Disitamab Vedotin and Tislelizumab were used in this study. This prospective clinical trial may bring new hope for the treatment of HER-2 positive CRC patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer
NCT05578287
Colorectal Cancer
RECRUITING
PHASE2
Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy
NCT05350917
HER2-positive or Mutated Advanced Colorectal Cancer
NOT_YET_RECRUITING
PHASE2
Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer
NCT07059338
HER2 Positive
Colorectal Cancer (CRC)
NOT_YET_RECRUITING
PHASE2
Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer
NCT05160727
Mismatch Repair-proficient
Colorectal Cancer Metastatic
Microsatellite Stable
UNKNOWN
PHASE2
RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer
NCT05785325
Colorectal Cancer
UNKNOWN
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Colorectal Neoplasms
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Combination of Disitamab Vedotin and Tislelizumab
Disitamab Vedotin 2.0mg/kg q2w+Tislelizumab 400mg q6w. The treatment of Disitamab Vedotin + Tislelizumab will continue until the tumor progression confirmed by imaging, or up to 2 years, or intolerable toxic reactions, or other conditions determined by the researchers.
Group Type
EXPERIMENTAL
Disitamab vedotin
Intervention Type
DRUG
2.0mg/kg，q2w
Tislelizumab
Intervention Type
DRUG
400mg，q6w
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Disitamab vedotin
2.0mg/kg，q2w
Intervention Type
DRUG
Tislelizumab
400mg，q6w
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
RC48
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Signed the consents voluntarily;
2. All genders, age 18 or above;
3. Histological or cytological documentation of local advanced or metastatic unresectable colorectal carcinoma;
4. Patients with HER-2 overexpression (HER-2 IHC 2+ or IHC 3+) detected by immunohistochemistry; Resampling is recommended for samples over 3 years.
5. Subjects must have failed at treatments including fluoropyrimidine, oxaliplatin and irinotecan; For adjuvant or neoadjuvant chemotherapy, if disease progression occurs during treatment or within 6 months after treatment, it will be recorded as a first-line treatment;
6. Patients who have used anti-PD-1 or anti-PD-L1 inhibitors can be selected after stopping the treatment for more than 6 months; Patients who have used other anti HER-2 drugs with different mechanisms can be selected.
7. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1.is necessary
8. Life expectancy of at least 3 months.
9. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
10. Have sufficient heart, lung, liver and kidney functions, and the laboratory examination within 14 days before screening meets the following indicators:
i. Hemoglobin Hb ≥ 90 g/L ii. Neutrophil count ANC ≥ 1.5\*10\^9 /L iii. Platelet count PLT ≥ 80\*10\^9 /L iv. Albumin ALB ≥ 35 g/L v. Alanine aminotransferase ALT and aspartate aminotransferase AST ≤ 2.5 times the upper limit of the normal range, and liver metastasis patients ≤ 5 times the upper limit of the normal range.
vi. Total bilirubin ≤ 1.5 times, or 2 times the upper limit of normal. vii. Creatinine Scr ≤ upper limit of normal range. viii. Prothrombin: PT-INR ≤ 2.3 or PT \< 6 seconds compared with normal control
11. Subjects must complete the treatment and follow-up on schedule. according to the research plan.
12. No brain metastasis, no spinal cord compression.
13. Subjects agree to use blood samples for study analysis.
14. Women of childbearing age must be negative in pregnancy test and willing to take effective contraceptive measures during the study period.
2. All genders, age 18 or above;
3. Histological or cytological documentation of local advanced or metastatic unresectable colorectal carcinoma;
4. Patients with HER-2 overexpression (HER-2 IHC 2+ or IHC 3+) detected by immunohistochemistry; Resampling is recommended for samples over 3 years.
5. Subjects must have failed at treatments including fluoropyrimidine, oxaliplatin and irinotecan; For adjuvant or neoadjuvant chemotherapy, if disease progression occurs during treatment or within 6 months after treatment, it will be recorded as a first-line treatment;
6. Patients who have used anti-PD-1 or anti-PD-L1 inhibitors can be selected after stopping the treatment for more than 6 months; Patients who have used other anti HER-2 drugs with different mechanisms can be selected.
7. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1.is necessary
8. Life expectancy of at least 3 months.
9. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
10. Have sufficient heart, lung, liver and kidney functions, and the laboratory examination within 14 days before screening meets the following indicators:
i. Hemoglobin Hb ≥ 90 g/L ii. Neutrophil count ANC ≥ 1.5\*10\^9 /L iii. Platelet count PLT ≥ 80\*10\^9 /L iv. Albumin ALB ≥ 35 g/L v. Alanine aminotransferase ALT and aspartate aminotransferase AST ≤ 2.5 times the upper limit of the normal range, and liver metastasis patients ≤ 5 times the upper limit of the normal range.
vi. Total bilirubin ≤ 1.5 times, or 2 times the upper limit of normal. vii. Creatinine Scr ≤ upper limit of normal range. viii. Prothrombin: PT-INR ≤ 2.3 or PT \< 6 seconds compared with normal control
11. Subjects must complete the treatment and follow-up on schedule. according to the research plan.
12. No brain metastasis, no spinal cord compression.
13. Subjects agree to use blood samples for study analysis.
14. Women of childbearing age must be negative in pregnancy test and willing to take effective contraceptive measures during the study period.
Exclusion Criteria
1. Subjects are severe malnutrition or need tube feeding.
2. Major surgery has been performed within 30 days before treatment.
3. Previous treatment with anti-PD-1 / PD-L1 inhibitor, anti-CTLA-4 inhibitor, ADC drugs targeting HER-2 such as RC48 and T-DM1 within 6 months.
4. Other malignant tumors within 2 years and without cure (Except for patients with other early-stage tumors, after radical treatment, whom the researchers assess the recurrence risk of in the short term is small);
5. Subjects have active autoimmune system diseases that need systemic hormone therapy or anti autoimmune drug therapy.
6. Subjects with immunodeficiency or receiving systemic steroid therapy (prednisone \> 10 mg / day or other equivalent drugs) or other forms of immunosuppressive therapy 7 days before the first dose of combination therapy in this study;
7. Subjects with active infection and still need systemic treatment 7 days before the first dose of therapy in this study.
8. Subjects with uncontrollable systemic diabetes.
9. Subjects with interstitial lung disease, non infectious pneumonia or pulmonary fibrosis;
10. Subjects who have received allogeneic organ or stem cell transplantation in the past.
11. Subjects allergic to the drugs or related components involved in this study.
12. Participating in other interventional clinical studies.
13. The previous anti-tumor related adverses do not return to grade 1 in CTCAE before the first combination therapy.
14. Subjects who have uncontrolled hypertension by drugs, that is, systolic blood pressure ≥ 140 mmHg and / or diastolic blood pressure ≥ 90 mmHg.
15. Thrombotic or hemorrhagic tendency or history within 60 days before the first medication, regardless of the severity.
16. Any serious or unstable medical condition#mental illness or known active alcohol or drug abuse or dependence.
2. Major surgery has been performed within 30 days before treatment.
3. Previous treatment with anti-PD-1 / PD-L1 inhibitor, anti-CTLA-4 inhibitor, ADC drugs targeting HER-2 such as RC48 and T-DM1 within 6 months.
4. Other malignant tumors within 2 years and without cure (Except for patients with other early-stage tumors, after radical treatment, whom the researchers assess the recurrence risk of in the short term is small);
5. Subjects have active autoimmune system diseases that need systemic hormone therapy or anti autoimmune drug therapy.
6. Subjects with immunodeficiency or receiving systemic steroid therapy (prednisone \> 10 mg / day or other equivalent drugs) or other forms of immunosuppressive therapy 7 days before the first dose of combination therapy in this study;
7. Subjects with active infection and still need systemic treatment 7 days before the first dose of therapy in this study.
8. Subjects with uncontrollable systemic diabetes.
9. Subjects with interstitial lung disease, non infectious pneumonia or pulmonary fibrosis;
10. Subjects who have received allogeneic organ or stem cell transplantation in the past.
11. Subjects allergic to the drugs or related components involved in this study.
12. Participating in other interventional clinical studies.
13. The previous anti-tumor related adverses do not return to grade 1 in CTCAE before the first combination therapy.
14. Subjects who have uncontrolled hypertension by drugs, that is, systolic blood pressure ≥ 140 mmHg and / or diastolic blood pressure ≥ 90 mmHg.
15. Thrombotic or hemorrhagic tendency or history within 60 days before the first medication, regardless of the severity.
16. Any serious or unstable medical condition#mental illness or known active alcohol or drug abuse or dependence.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Affiliated Hospital with Nanjing Medical University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gu Yanhong
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital with Nanjing Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Changzhou NO.2 People's Hospital
Changzhou, Jiangsu, China
Site Status
RECRUITING
The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University
Huai'an, Jiangsu, China
Site Status
RECRUITING
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China
Site Status
RECRUITING
the Third Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Site Status
RECRUITING
Xuzhou Central Hospital
Xuzhou, Jiangsu, China
Site Status
RECRUITING
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
China
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Shiyun Cui, Dr
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hua Jiang
Role: primary
Xiaomin Zhong
Role: primary
Wenwei Hu
Role: primary
Yuan Yuan
Role: primary
Zhiyu Chen
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
Reference Type
BACKGROUND
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.
Reference Type
BACKGROUND
Diagnosis And Treatment Guidelines For Colorectal Cancer Working Group CSOCOC. Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version). Chin J Cancer Res. 2019 Feb;31(1):117-134. doi: 10.21147/j.issn.1000-9604.2019.01.07. No abstract available.
Reference Type
BACKGROUND
Messersmith WA. NCCN Guidelines Updates: Management of Metastatic Colorectal Cancer. J Natl Compr Canc Netw. 2019 May 1;17(5.5):599-601. doi: 10.6004/jnccn.2019.5014.
Reference Type
BACKGROUND
Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Kohne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Osterlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taieb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235. Epub 2016 Jul 5.
Reference Type
BACKGROUND
Piawah S, Venook AP. Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer. 2019 Dec 1;125(23):4139-4147. doi: 10.1002/cncr.32163. Epub 2019 Aug 21.
Reference Type
BACKGROUND
Shirley M. Fruquintinib: First Global Approval. Drugs. 2018 Nov;78(16):1757-1761. doi: 10.1007/s40265-018-0998-z.
Reference Type
BACKGROUND
Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020 Jan;17(1):33-48. doi: 10.1038/s41571-019-0268-3. Epub 2019 Sep 23.
Reference Type
BACKGROUND
Rakha EA, Pinder SE, Bartlett JM, Ibrahim M, Starczynski J, Carder PJ, Provenzano E, Hanby A, Hales S, Lee AH, Ellis IO; National Coordinating Committee for Breast Pathology. Updated UK Recommendations for HER2 assessment in breast cancer. J Clin Pathol. 2015 Feb;68(2):93-9. doi: 10.1136/jclinpath-2014-202571. Epub 2014 Dec 8.
Reference Type
BACKGROUND
Ruschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012 May;25(5):637-50. doi: 10.1038/modpathol.2011.198. Epub 2012 Jan 6.
Reference Type
BACKGROUND
Mar N, Vredenburgh JJ, Wasser JS. Targeting HER2 in the treatment of non-small cell lung cancer. Lung Cancer. 2015 Mar;87(3):220-5. doi: 10.1016/j.lungcan.2014.12.018. Epub 2015 Jan 8.
Reference Type
BACKGROUND
Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, McCall SJ, Penault-Llorca F, Srock S, Bardelli A, Trusolino L. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018 May 1;29(5):1108-1119. doi: 10.1093/annonc/mdy100.
Reference Type
BACKGROUND
Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M, Rugge M, Grigioni W, Bencardino K, Lonardi S, Zagonel V, Leone F, Noe J, Ciardiello F, Pinto C, Labianca R, Mosconi S, Graiff C, Aprile G, Frau B, Garufi C, Loupakis F, Racca P, Tonini G, Lauricella C, Veronese S, Truini M, Siena S, Marsoni S, Gambacorta M. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol. 2015 Nov;28(11):1481-91. doi: 10.1038/modpathol.2015.98. Epub 2015 Oct 9.
Reference Type
BACKGROUND
Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, Zagonel V, Leone F, Depetris I, Martinelli E, Troiani T, Ciardiello F, Racca P, Bertotti A, Siravegna G, Torri V, Amatu A, Ghezzi S, Marrapese G, Palmeri L, Valtorta E, Cassingena A, Lauricella C, Vanzulli A, Regge D, Veronese S, Comoglio PM, Bardelli A, Marsoni S, Siena S. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Jun;17(6):738-746. doi: 10.1016/S1470-2045(16)00150-9. Epub 2016 Apr 20.
Reference Type
BACKGROUND
Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019 Apr;20(4):518-530. doi: 10.1016/S1470-2045(18)30904-5. Epub 2019 Mar 8.
Reference Type
BACKGROUND
Sartore-Bianchi A, Lonardi S, Martino C, Fenocchio E, Tosi F, Ghezzi S, Leone F, Bergamo F, Zagonel V, Ciardiello F, Ardizzoni A, Amatu A, Bencardino K, Valtorta E, Grassi E, Torri V, Bonoldi E, Sapino A, Vanzulli A, Regge D, Cappello G, Bardelli A, Trusolino L, Marsoni S, Siena S. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. ESMO Open. 2020 Sep;5(5):e000911. doi: 10.1136/esmoopen-2020-000911.
Reference Type
BACKGROUND
Nakamura Y, et al. TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumor tissue or circulating tumor DNA (ctDNA): a GOZILA sub-study. Annals of Oncology (2019) 30 (suppl_5): v198-v252.
Reference Type
BACKGROUND
Strickler JH, et al. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial. Annals of Oncology (2019) 30 (suppl_5): v198-v252.
Reference Type
BACKGROUND
Siena S, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, Yamaguchi K, Nishina T, Fakih M, Elez E, Rodriguez J, Ciardiello F, Komatsu Y, Esaki T, Chung K, Wainberg Z, Sartore-Bianchi A, Saxena K, Yamamoto E, Bako E, Okuda Y, Shahidi J, Grothey A, Yoshino T; DESTINY-CRC01 investigators. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021 Jun;22(6):779-789. doi: 10.1016/S1470-2045(21)00086-3. Epub 2021 May 4.
Reference Type
BACKGROUND
Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, Shi B, Liu J, He Z, Yu G, Ying J, Han W, Hu C, Ling Y, Chi Z, Cui C, Si L, Fang J, Zhou A, Guo J. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res. 2021 Jan 1;27(1):43-51. doi: 10.1158/1078-0432.CCR-20-2488. Epub 2020 Oct 27.
Reference Type
BACKGROUND
Sheng XN, He ZS, Han WQ, et al. An Open-label, Single-arm, Multicenter, Phase Ⅱ Study of RC48 to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer (RC48-C009) [EB/OL]. ASCO 2021, abstract 4584.
Reference Type
BACKGROUND
Zhou L, Xu HY, Yan XQ, et al. Preliminary results of RC48 combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma RC48-C014[EB/OL]. ASCO 2021, abstract 4534.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KEEP-G 07
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer
NCT05193292
UNKNOWN
PHASE2
Chemotherapy and Tislelizumab With Split-course HFRT for Locally Advanced Rectal Cancer
NCT05176964
RECRUITING
Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer
NCT06017583
RECRUITING
PHASE3
A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer
NCT06312982
RECRUITING
PHASE2/PHASE3
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
NCT05799443
UNKNOWN
PHASE2
Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer
NCT05845268
RECRUITING
PHASE2
Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study
NCT06390982
NOT_YET_RECRUITING
PHASE2
Strengthening the Spleen and Reducing Phlegm Method in Improving Radical Resection Rate of Colorectal Cancer
NCT03716063
UNKNOWN
PHASE3
Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer
NCT05479240
NOT_YET_RECRUITING
PHASE2
MRD-positive Colorectal Cancer Patients Combined With Personalized Immune Regulation Diagnosis
NCT06434376
NOT_YET_RECRUITING
EARLY_PHASE1
Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors
NCT03177382
UNKNOWN
PHASE3
Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study
NCT05998122
NOT_YET_RECRUITING
PHASE2
Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab
NCT06304545
NOT_YET_RECRUITING
PHASE2
Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients
NCT05426811
NOT_YET_RECRUITING
PHASE1/PHASE2
Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer
NCT06333769
COMPLETED
PHASE2
Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC
NCT06599827
NOT_YET_RECRUITING
PHASE2
A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer
NCT04543695
ACTIVE_NOT_RECRUITING
PHASE2
Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer
NCT05360277
RECRUITING
PHASE2
Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC
NCT05155124
UNKNOWN
PHASE1
Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.
NCT04911517
UNKNOWN
PHASE2
Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC
NCT04924179
UNKNOWN
PHASE2
Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical
NCT02748772
UNKNOWN
PHASE3
Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.
NCT06894797
RECRUITING
NA
Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using MR Guided Linear Accelerator
NCT05338866
ENROLLING_BY_INVITATION